New antibiotic shows promise against superbug in major hospital study
NCT ID NCT07226557
First seen Nov 10, 2025 · Last updated Jun 01, 2026 · Updated 28 times
Summary
This study looks at whether a newer antibiotic called cefiderocol can save more lives than the current best treatments for a dangerous, drug-resistant bacteria (CRAB). Researchers will analyze data from about 5,000 hospitalized adults to compare death rates after 7 days of treatment. The goal is to find a more effective way to control these serious infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTIMICROBIAL DRUG RESISTANCE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.